IMMH-010
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2020 (NCT04343859)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1=C(OCc2cccc(-c3ccccc3)c2Br)C=C(OCc2cccnc2)C(CN[C@@H](CO)C(=O)OC(C)C)C1- Mol. weight
- 621.57 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095184 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04343859 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | Shantou University, Tianjin Chase Sun Pharmaceutical Co., LTD |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Tianjin Chase Sun Pharmaceutical Co., LTD | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1